度普利尤单抗在血嗜酸性粒细胞≥500细胞·µL-1哮喘患者中的疗效与安全性
本文为Eur Respir J发表的文献摘要,指出度普利尤单抗在血嗜酸性粒细胞≥500 cells·µL-1的哮喘患者中耐受良好并改善临床结局,且临床结局的改善与嗜酸性粒细胞计数相关。该文提及GINA指南推荐生物制剂作为重度2型炎症哮喘的附加治疗,并介绍度普利尤单抗阻断IL-4和IL-13共享受体成分的作用机制,但摘要未报告具体疗效数值。
要点
- 度普利尤单抗在血嗜酸性粒细胞≥500 cells·µL-1的哮喘患者中耐受良好并改善临床结局。
- 临床结局的改善与嗜酸性粒细胞计数相关。
- GINA指南推荐生物制剂作为重度2型炎症哮喘的附加治疗。
核心结论
- 度普利尤单抗在血嗜酸性粒细胞≥500 cells·µL-1的哮喘患者中耐受良好并改善临床结局,临床结局改善与嗜酸性粒细胞计数相关。
主要发现
- 度普利尤单抗在血嗜酸性粒细胞≥500 cells·µL-1的哮喘患者中耐受良好并改善临床结局。
- 临床结局的改善与嗜酸性粒细胞计数相关,显示度普利尤单抗在高嗜酸性粒细胞患者中的疗效。
关键数值与推荐
- GINA指南推荐生物制剂作为重度2型炎症哮喘患者在高剂量吸入性糖皮质激素治疗后仍未控制时的附加治疗。
- 血或痰嗜酸性粒细胞升高及呼出气一氧化氮(FeNO)升高可作为2型炎症的替代标志物,用于识别可能适合生物制剂治疗的患者。
- 度普利尤单抗是完全人源VelocImmune衍生单克隆抗体,阻断白细胞介素-4和-13的共享受体成分,抑制其信号传导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dupilumab is well tolerated and improves clinical outcomes in patients with asthma and high eosinophils (≥500 cells·µL−1). Improvements in clinical outcomes correlate with eosinophil counts, demonstrating dupilumab efficacy in those with high eosinophils. https://bit.ly/3Jxvicb Uncontrolled, moderate-to-severe asthma in patients with high baseline blood eosinophils (≥500 cells·µL−1) can be difficult to treat [1]. Global Initiative for Asthma guidelines recommend biologics as add-on therapy for patients with severe type 2 inflammatory asthma that remains uncontrolled despite treatment with high-dose inhaled corticosteroids [2]. Surrogate markers of type 2 inflammation, such as elevated levels of blood or sputum eosinophils and fractional exhaled nitric oxide (FeNO) can be used to identify patients with a type 2 signature who might be eligible for such treatment [1–3]. Several biologics are now available that target different molecules in type 2 inflammatory pathways, notably IgE and type 2 cytokines [1–3]. One of these, dupilumab, is a fully human VelocImmune-derived [4, 5] monoclonal antibody that blocks the shared receptor component for interleukin-4 and -13, cytokines that are key and central drivers of type 2 inflammation in multiple diseases, thus inhibiting their signalling [6, 7].
引用
- Rabe KF, Pavord ID, Castro M, et al. Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL-1. Eur Respir J. 2022. PMID: 35487538. doi:10.1183/13993003.02577-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。